Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the ...
Baar, Switzerland Wednesday, March 4, 2026, 17:00 Hrs [IST] ...
Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently ...
A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...
Key HighlightsResearchers identified distinct tumor-immune ecologies that differentiate stable disease from progressive disease in non-small cell lung ...
News-Medical.Net on MSN
Distinct spatial tumor–immune ecosystems predict lung cancer treatment response
Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.
Lung cancer is now the leading cause of cancer deaths in the United States, claiming more lives than several other major ...
Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results